Human infections due to *Mycobacterium lentiflavum*: first report in Iran

Shamaei M1, Marjani M1, Farnia P2, Tabarsi P2, Mansouri D1,3

1Clinical Tuberculosis and Epidemiology Research Center; 2Mycobacteriology Research Center; 3Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: January 2010, Accepted: February 2010.

ABSTRACT

Non-tuberculosis mycobacteria (NTM), as certain species of mycobacteria, can affect human in several ways. In the preceding years, the rate of NTM detection has risen in both immunocompromised and immunocompetent patients. On the other hand, several reports have debated the possibility of co-infection of both *Mycobacterium tuberculosis* (MTB) and NTM in individuals that puts the role of NTM in disease manifestations under question. Moreover, it is now proven that some of the cases that are identified as anti-TB treatment failure or suspected for drug resistance are actually NTM.

**Keywords:** *Mycobacterium lentiflavum*, NTM, Iran.

INTRODUCTION

Non-tuberculous mycobacteria, as certain species of mycobacteria, can affect humans in several ways (1-3). Though they are thought to affect the immunocompromised patients more frequently, several studies have demonstrated NTM as the etiological agent of disease in immunocompetent hosts (4-6).

In the past few years, rate of NTM detection has risen in both immunocompromised and immunocompetent patients. This may be partly attributed to advances in mycobacteriologic detection methods, increase in acquired immunodeficiency cases (either HIV infection or use of immunosuppressive drugs), or just simply actual increase in NTM infection itself (1).

On the other hand, several reports have debated the possibility of co-infection of both MTB and NTM in an individual that puts the role of NTM in disease manifestations under question. Moreover, it has now been proven that some cases that are identified as anti-TB treatment failure or suspected for drug resistance are actually NTM (1).

A broad spectrum of non-tuberculous mycobacteria live freely in our surrounding environment (1-3). However, they may cause disease in both human or animals. Human to human transmission of NTM has not yet been confirmed. Though, animal to human transmission has been suggested in some reports (7-8).

So, role of NTM, particularily when public health issues are concerned, should be emphasized despite the fact that no definitive route of transmission is yet proposed (i.e., either human to human or animal to human).

NTM and the diseases they cause have received much attentions world-wide during the past decade. Also, with regard to the enormity of varieties of these organisms, the sporadic diseases caused by them, and the difficulties in detecting such bacilli, the reported cases are still somewhat few. Therefore, any kind of disease caused by NTM, especially those presenting with clinical manifestations during their involvement and rare cases would merit being reported for further considerations.

*Mycobacterium lentiflavum* was first identified in 1996 as a distinct strain (9). Since then, several cases of infections with this bacilli have been reported with skin or lymph node involvement. Also, it has been isolated from pleural effusions, ascites, and from lung tissues (10-12).

This paper is the first report of documented *M. lentiflavum* infection from Iran.

Case Report

A 44 year-old Iranian woman who was resident of
Kurdestan province in the west of Iran, presented to our center with cough, scanty sputum, left unilateral pleuritic chest pain, anorexia and weight loss for the last three months that had exacerbated in the preceding couple weeks.

In 1999, her symptoms first started and thus she underwent an assessment for TB. The clinical manifestations typical for and the radiological findings consistent with TB, accompanied with positive sputum smear for Acid Fast Bacilli, led to the initiation of anti-TB treatment. She had received the WHO CAT I regimen for six months at a peripheral health care center in Iran. Since then, the patient has been treated with anti-TB medication three times, including CAT II regimen, due to recurrence of clinical manifestations and each time the treatment course was completed and cure was documented by obtaining negative sputum smear negative for AFB.

For the last three months, and the first time after her third treatment regimen, her symptoms re-emerged. She was evaluated at the peripheral health care center and due to a positive smear for AFB, was referred to our center as a suspected case for MDR-TB.

At admission, she appeared quite cachectic. There was no cervical or axillary lymphadenopathy. In chest auscultation, inspiratory crackles were detected mainly on the left middle and lower regions. Tuberculin skin test (TST) performed with PPD revealed 10 mm of induration. No BCG vaccination scar was detected.

As a suspected MDR-TB case and according to our routine protocol for these patients, mycobacteriologic studies (including sputum smears and cultures, and Drug Susceptibility Testing (DST)), polymerase chain reaction (PCR) specific for MTB, and other identification tests were requested. The sputum smears rendered a 2+ result.

The patient, as a suspected MDR-TB case, underwent the standardized anti-TB regimen consisting of cycloserine, ofloxacin, prothionamide, and amikacin.

The anti-HIV antibody test was negative. Sputum smear was 2+ for AFB. Chest X-ray showed bilateral fibrocavitary destructive changes and biapical pleural thickening. Chest CT scan revealed fibrocavitary destructive change in both upper lobes, heart and mediastane shift toward left side, biapical pleural thickening and loss of volume seen with compensatory over aerated and emphysematous lower lobe changes (Fig. 1).

Drug susceptibility testing (DST) demonstrated resistance to all first line anti-TB drugs. PCR for MTB was negative and with further evaluations using identification methods, *Mycobacterium lentiflavum* was identified in the specimens.

As *Mycobacterium lentiflavum* had been isolated, the treatment regimen changed to clarithromycin, Ofloxacin, and amikacin. The sputum culture turned negative after two months of treatment and has remained so for the time being while the patient has received more than six months medication.

Specimens obtained from the patient were cultured on the Lowenstein – Jensen (L.J.) slants so that 100-120 colonies grew. Whenever polymerase chain-reaction using RFLP-IS6110 probe and spoligotyping were negative, conventional biochemical tests as identification methods (13) were performed for both the patient strain as well as standard NTM (obtained from Department of Mycobacteriology, National...
DISCUSSION

NTM most commonly presents with pulmonary manifestations. However, lymph node, skin, soft tissue involvement as well as disseminated disease are of clinical importance (1). Mycobacterium lentiflavum was first identified in 1996 as a distinct strain. Since then, several cases of infections with this bacilli have been reported with skin or lymph node involvements. Also, it has been isolated from pleural effusions, ascites, and from lung tissue.

However, the pulmonary disease caused by M. lentiflavum are few. Furthermore, most of the reported cases were detected in immunocompromised patients. It is of note that this case occurred in an immunocompetent patient and there are few such reports available (15) As well, after administering the appropriate treatment for M. lentiflavum, the clinical condition of the patient improved, her sputum smears and culture turned negative; therefore, this is among few cases that the M. lentiflavum treatment outcome is determined.

The notable characteristics of our case was that she had the history of several anti-TB treatments. According to NTP, anti-TB treatment is initiated based on positive smears, culture and DST are not routinely performed. So, we do not know about the type of mycobacterium in her previous illnesses.

Accordingly, in patients who are treated according to NTP (merely based on positive smears), NTM should be kept in mind especially if the patient does not properly respond to the standard anti-TB regimens. Moreover, despite some recommendations for treatment of M. lentiflavum, it seems that further evaluations should be developed to find the optimal therapeutic protocol and regimen.

REFERENCES

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculosis Mycobacterial Diseases. Am J Respir Crit Care Med 2003; 175: 367-416.
2. McNabb AD, Eisler K, Adile M, Amos M, Rodrigues G, Stephens WA, Black I, Renton J. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42: 3000-3011.
3. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990′s. Clin Microbiol Rev 2003; 2: 319-354.
4. World Health organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006. 361. Geneva, Switzerland: WHO 2006.
5. Matos ED, Santana MA, de Santana MC, Mamede P, de Lira Bezerra B, Panao ED, et al. Nontuberculosis Mycobacteria at a Multi-resistant Tuberculosis Reference Center in Bahia: Clinical Epidemiological Aspects. Braz J Infect Dis 2004 Aug; 8 (4): 296-304.
6. Kim SJ. Drug susceptibility testing in tuberculosis: methods and reliability of results. European Respir J. 2005; 25: 564-569.
7. Lind A, Larsson LO, Bentzon MW, Magnusson M, Olofson J, Sjögren I, et al. Sensitivity to sensitins and tuberculin in Swedish children. I. A study of school children in an urban area Tuberce 1991; 72: 29-36.
8. Reznikov M, Robinson E. Serologically identical Battey mycobacteria from sputa of healthy piggery workers and lesions of pigs. Aust Vet J 1970; 46: 606-607.
9. Springer B, Wu WK, Bodmer T, Hasse G, Pfyffer GE, Kroppenstedt RM, et al. Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol 1996; 34: 1100-1107.
10. Haase G, Kentrup H, Skopnik H, Springer B, Bottger EC. Mycobacterium lentiflavum: an etiologic agent of cervical lymphadenitis. Clin Infect Dis 1997; 25: 1245-6.
11. Tortoli E, Mattel R, Russo C, Scarparo C. Mycobacterium Lentiflavum an emerging pathogen? J Infect 2005; 52: 185-187.
12. Safdar A, Han XY. Mycobacterium lentiflavum, a recently identified slow-growing mycobacterial species: clinical significance in immunosuppressed cancer patients and summary of reported cases of infection. Eur J Clin Microbiol Infect Dis 2005; 24: 554-558.
13. Holt JG, Krieg NR, Sneath PHA, Staley JT, William ST, editors. Bergey’s manual of systematic bacteriology Baltimore: Williams & Wilkins. 1994, 597P.
14. Kent PT, Kubica GP, Public health Mycobacteriology: A guide for the level III laboratory, Department of Health and Human Services, Centers for Diseases Control, Atlanta, GA. 1985-P:36-138.
15. Molteni C, Gazzola L, Cesari M, Lombardi A, Salerno F, Tortoli E, et al. Mycobacterium lentiflavum infection in immunocompetent patient. Emerg Infect Dis 2005; 11:119-122.